Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects
NCT ID: NCT04982913
Last Updated: 2023-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
118 participants
INTERVENTIONAL
2021-08-24
2022-10-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
NCT01231620
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
NCT00921726
Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects
NCT04729764
A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects
NCT00540501
Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With Influenza
NCT06099873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single dose of HEC116094（Part A, Cohort 1）
Healthy subjects receive sinele dose of HEC116094
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Single dose of HEC116094（Part A, Cohort 2）
Healthy subjects receive sinele dose of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Single dose of HEC116094（Part A, Cohort 3）
Healthy subjects receive sinele dose of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Single dose of HEC116094（Part A, Cohort 4，Fed/Fasting）
Following an overnight fast of at least 10 hours, a single dose of HEC116094 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Single dose of HEC116094（Part A, Cohort 5）
Healthy subjects receive sinele dose of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Single dose of HEC116094（Part A, Cohort 6）
Healthy subjects receive sinele dose of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Single dose of HEC116094（Part A, Cohort 7）
Healthy subjects receive sinele dose of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Mulltiple doses HEC116094（ Part B, Cohort 1）
Healthy subjects receive multiple doses of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Mulltiple doses HEC116094（ Part B, Cohort 2）
Healthy subjects receive multiple doses of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Mulltiple doses HEC116094（ Part B, Cohort 3）
Healthy subjects receive multiple doses of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Mulltiple doses HEC116094（ Part B, Cohort 4）
Healthy subjects receive multiple doses of HEC116094 or matching placebo
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
The interaction with Oseltamivir of HEC116094（ Part C）
Healthy subjects received HEC116094 in cycle 1, Oseltamivir in cycle 2, and a combination of HEC116094 and Oseltamivir in cycle 3.There are washout periods between the first cycle and the second cycle and between the second cycle and the third cycle
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HEC116094
Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female subjects who are not pregnant or lactating and male subjects whose female partners are fertile shall voluntarily take effective contraceptive measures from the date of signing the informed consent form to 3 months after the medication.
* When signing the informed consent, 18 years old ≤the age≤45 years old(including the critical value), gender is not limited.
* Male body weight ≥50kg, female body weight ≥45kg, and body mass index (BMI) in the range of 18-28 kg/m2 (including the critical value).
* No clinical significance of vital signs, physical examination, laboratory examination, electrocardiogram, ultrasound abdomen and chest X-ray (posterior and anterior) results.
Exclusion Criteria
* Those who are known to have allergy history or allergy constitution to the test preparation and any of its components or related preparations.
* Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
* Positive results from urine drug screen test.
* Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
* Subjects who plan to receive or have had organ transplants.
* Subjects considered by the investigator to have other factors unsuitable for participation in this study.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunshine Lake Pharma Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Shanghai xuhui district central hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEC116094-P-01/CRC-C2104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.